GlassScriptPhysician profile
Tami J Barton
NPI 1922538933
$520.34
in general payments reported to CMS, 2019-2025
15 companies · $85.45 in 2025
The $85.45 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.02 · 2022: $239 · 2023: $107 · 2024: $44.50 · 2025: $85.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $75.57 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $62.42 | 2023-2025 | Gardasil 9, Proquad, Vaxelis |
| Novo Nordisk INC | $54.12 | 2022 | |
| Cranial Technologies, INC | $48.75 | 2023-2024 | Doc Band |
| Genentech USA, INC. | $44.02 | 2021 | |
| Abbott Laboratories | $34.09 | 2022 | |
| Sanofi Pasteur INC. | $33.41 | 2023-2025 | |
| Viiv Healthcare Company | $32.51 | 2025 | Cabenuva |
| Lilly USA, LLC | $29.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.32 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.56 | 2022 | |
| Seqirus USA INC | $16.23 | 2025 | Flucelvax |
| Glaxosmithkline, LLC. | $15.03 | 2023 | Bexsero, Pediarix |
| Astrazeneca Pharmaceuticals LP | $14.61 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.